drugset / Trial / NCT02695810

The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes

NCT02695810

RandomizedParallel-groupOpen-labelPrevention

Summary

The overall objective is to compare the short-term (3 months) effectiveness of three glucose-lowering interventions (dapagliflozin, metformin and physical activity) on glucose variability, body composition, and cardiometabolic risk factors in overweight or obese individuals with pre-diabetes (HbA1c 5.7-6.4% / 39-47 mmol/mol).

Timeline

Start
2016-02-24
Primary completion
2018-09-20
Completion
2019-01-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg
Comparator Metformin Small molecule 850 mg